Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Sep;26(5):667-71.
doi: 10.3109/14397595.2016.1147405. Epub 2016 Mar 4.

Pregnancy outcomes after exposure to tocilizumab: A retrospective analysis of 61 patients in Japan

Ken Nakajima  1   2   3 , Omi Watanabe  1   4 , Mayumi Mochizuki  3 , Ayako Nakasone  5 , Nobuhiko Ishizuka  5 , Atsuko Murashima  1   4
Affiliations

Pregnancy outcomes after exposure to tocilizumab: A retrospective analysis of 61 patients in Japan

Ken Nakajima et al. Mod Rheumatol. 2016 Sep.

Abstract

Objectives: To assess the effects of tocilizumab on pregnancy outcomes in Japanese patients with rheumatic disease.

Methods: Data from Chugai's tocilizumab safety database (April 2005 to October 2014) were retrospectively analyzed to identify pregnancy outcomes in patients exposed to tocilizumab.

Results: Data were available for 61 pregnancies exposed to tocilizumab, and outcomes were reported for 50 of those pregnancies. In 36 births, no congenital anomalies were identified; however, six neonatal abnormalities were reported: five cases of low birth weight (<2500 g) and one case of neonatal asphyxia. Of 36 births, tocilizumab was resumed during lactation in two patients, with no subsequent adverse events reported in newborns. The spontaneous abortion rate was 18.0% (9 of 50 pregnancies), which is comparable to the rate in the general population. The five terminated pregnancies included one case of caudal regression syndrome.

Conclusions: The present retrospective study of 61 pregnancies exposed to tocilizumab at conception indicated no increased rates of spontaneous abortion or congenital abnormalities in patients with rheumatic disease. However, further study is necessary to confirm the benefit-risk profile of tocilizumab treatment during pregnancy.

Keywords: Abortions; Pregnancy outcome; Rheumatoid arthritis; Tocilizumab.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Summary of birth event.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Sangha O. Epidemiology of rheumatic diseases. Rheumatology (Oxford) 2000;39(Suppl 2):3–12. - PubMed
    1. Lockshin MD. Invited review: sex ratio and rheumatic disease. J Appl Physiol (1985) 2001;91:2366–73. - PubMed
    1. Myasoedova E, Crowson CS, Kremers HM, Therneau TM, Gabriel SE. Is the incidence of rheumatoid arthritis rising?: results from Olmsted County, Minnesota, 1955–2007. Arthritis Rheum. 2010;62:1576–82. - PMC - PubMed
    1. Golding A, Haque UJ, Giles JT. Rheumatoid arthritis and reproduction. Rheum Dis Clin North Am. 2007;33:319–43. - PubMed
    1. Ostensen M, Villiger PM. The remission of rheumatoid arthritis during pregnancy. Semin Immunopathol. 2007;29:185–91. - PubMed

Substances

-